Chernett Jorey has made a significant move by purchasing 14,000 shares of Exagen Inc. at a price of $7.46 each, as reported in a recent SEC filing. This acquisition, which took place on October 19, 2026, demonstrates Jorey's confidence in the company's future and the medical laboratory services sector.
Jorey's total ownership in Exagen now stands at 2,618,540 shares, reflecting a robust commitment to the company. This transaction is notable as it comes amid increasing interest in the medical laboratory services industry, which is characterized by its focus on diagnostic testing and innovative healthcare solutions.
Background
Chernett Jorey is a significant shareholder in Exagen Inc., a company listed under the SEC file number 001-39049. Exagen operates in the medical laboratory services sector, providing essential diagnostic testing services. The company is incorporated in Delaware and has its fiscal year ending on December 31. Recent filings indicate that Jorey has been actively managing his stake in Exagen, with multiple transactions reported in the past months.
What the Filing Says
According to the SEC filing (accession number 0001193805-26-001382), Jorey acquired 14,000 shares on October 19, 2026. The filing notes, "These shares were purchased in multiple transactions at prices ranging from $7.44 to $7.48, rounded to the nearest cent, inclusive." This level of detail underscores Jorey’s proactive approach to his investments.
Impact
This transaction may affect Exagen's market perception, as significant purchases by insiders often signal confidence in a company's performance. Jorey, being a ten percent owner, holds considerable influence over the company’s direction. His actions could encourage other investors to take a closer look at Exagen's potential.
What's Next
The filing does not say what happens next regarding further transactions or plans for Exagen. However, Jorey's ongoing engagement with the company suggests he may continue to monitor and adjust his holdings as necessary.